The second largest generic pharmaceutical company in the U.S. by sales volume, Mylan continues to capitalize on its presence in that market, which is the world's largest. Mylan's North American businesses include Mylan Pharmaceuticals, which is based in Morgantown, W.Va., Mylan's business in Canada, Mylan Technologies and UDL Laboratories.
Mylan's Asia Pacific (APAC) presence includes market leading positions in Australia, through its Alphapharm subsidiary, Japan, the world's second largest pharmaceutical market, through its Mylan Seiyaku subsidiary, and New Zealand through its business in that country.
In addition, Mylan's strong active pharmaceutical ingredients (API) business, run by Mylan Laboratories Limited, is included in the company's APAC division. Headquartered in Hyderabad, India, Mylan Laboratories operates nine API and intermediate manufacturing facilities located in India and China.
Mylan operates in Europe, the Middle East and Africa (EMEA), with manufacturing, packaging, distribution and marketing capabilities throughout the region. The division consistently holds top-five positions in several markets, including a No. 1 position in France.
Mylan EMEA businesses include those that operate under the Mylan name in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Scandinavia, Slovakia, Slovenia, Spain, Sweden, Switzerland, South Africa and United Kingdom.
Mylan's other EMEA businesses include Arcana Arzneimittel, Generics Pharma Hellas, Gerard Laboratories and Qualimed. Docpharma, another Mylan business, distributes generic pharmaceuticals in Belgium, the Netherlands and Luxembourg.